| Year |
Citation |
Score |
| 2023 |
Tao Y, Budhipramono A, Huang J, Fang M, Xie S, Kim J, Khivansara V, Dominski Z, Tong L, De Brabander JK, Nijhawan D. Anticancer benzoxaboroles block pre-mRNA processing by directly inhibiting CPSF3. Cell Chemical Biology. PMID 37967558 DOI: 10.1016/j.chembiol.2023.10.019 |
0.306 |
|
| 2005 |
Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S, Belmont J, Arlinghaus R. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene. 24: 3246-56. PMID 15735695 DOI: 10.1038/Sj.Onc.1208500 |
0.518 |
|
| 2002 |
Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 21: 7137-46. PMID 12370803 DOI: 10.1038/Sj.Onc.1205942 |
0.569 |
|
| 2002 |
Hawk N, Sun T, Xie S, Wang Y, Wu Y, Liu J, Arlinghaus RB. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Cancer Research. 62: 386-90. PMID 11809685 |
0.522 |
|
| 2001 |
Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene. 20: 6188-95. PMID 11593427 DOI: 10.1038/Sj.Onc.1204834 |
0.567 |
|
| 1997 |
Xie S, Price JE, Luca M, Jean D, Ronai Z, Bar-Eli M. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene. 15: 2069-75. PMID 9366524 DOI: 10.1038/Sj.Onc.1201358 |
0.411 |
|
| 1996 |
Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Research. 56: 3426-30. PMID 8758906 |
0.533 |
|
| Show low-probability matches. |